Following review, we recommend reimbursement of vernakalant in the hospital setting.
Cost effectiveness analysis of a universal infant rotavirus vaccination programme in Ireland
Following a revision in price application we now consider agomelatine (Valdoxan®) cost effective under the Community Drugs schemes.
We consider ustekinumab cost effective for the treatment of moderate to severe plaque psoriasis in the Irish healthcare setting.
We do not believe that glucosamine sulfate (DONA®) is a cost effective therapy for the treatment of osteoarthritis in the Irish Healthcare setting.
Health Technology Assessment (HTA) of population-based colectoral cancer screening programme in Ireland.
We believe that there is currently insufficient evidence to support the reimbursement of this product under the Community Drugs Schemes.
Health Technology Assessment on the role of vaccination against human papillomavirus in reducing the risk of cervical cancer in Ireland.